CL2017003091A1 - Formulaciones tópicas para la entrega de compuestos inhibidores hedgehog y uso de los mismos - Google Patents

Formulaciones tópicas para la entrega de compuestos inhibidores hedgehog y uso de los mismos

Info

Publication number
CL2017003091A1
CL2017003091A1 CL2017003091A CL2017003091A CL2017003091A1 CL 2017003091 A1 CL2017003091 A1 CL 2017003091A1 CL 2017003091 A CL2017003091 A CL 2017003091A CL 2017003091 A CL2017003091 A CL 2017003091A CL 2017003091 A1 CL2017003091 A1 CL 2017003091A1
Authority
CL
Chile
Prior art keywords
hedgehog inhibitor
delivery
topical formulations
inhibitor compounds
monohidrico
Prior art date
Application number
CL2017003091A
Other languages
English (en)
Inventor
Marc Berry Brown
Cameron Robert Stevenson
Charles Rodney Greenaway Evans
Original Assignee
Pellepharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56148672&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2017003091(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pellepharm Inc filed Critical Pellepharm Inc
Publication of CL2017003091A1 publication Critical patent/CL2017003091A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

COMPOSICION QUE COMPRENDE UN COMPUESTO INHIBIDOR HEDGEHOG Y UN SISTEMA SOLVENTE QUE COMPRENDE UN ALCOHOL PRIMARIO MONOHIDRICO Y UN POLIOL O UN ALQUILEN GLICOL OLIGOMERICO Y UNA SOLUCION AMORTIGUADORA, ACIDO GRASO O ETER BICICLICO FUSIONADO; SISTEMA DE ADMINISTRACION TOPICA; METODOS PARA PREVENIR, TRATAR Y RETARDAR UN CARCINOMA.
CL2017003091A 2015-06-04 2017-12-04 Formulaciones tópicas para la entrega de compuestos inhibidores hedgehog y uso de los mismos CL2017003091A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562171117P 2015-06-04 2015-06-04
US201662275185P 2016-01-05 2016-01-05

Publications (1)

Publication Number Publication Date
CL2017003091A1 true CL2017003091A1 (es) 2018-11-09

Family

ID=56148672

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017003091A CL2017003091A1 (es) 2015-06-04 2017-12-04 Formulaciones tópicas para la entrega de compuestos inhibidores hedgehog y uso de los mismos

Country Status (13)

Country Link
US (3) US10369147B2 (es)
EP (1) EP3302428A1 (es)
JP (2) JP6796638B2 (es)
AU (1) AU2016271468B2 (es)
BR (1) BR112017026103B1 (es)
CA (1) CA2988289C (es)
CL (1) CL2017003091A1 (es)
HK (1) HK1253345A1 (es)
IL (1) IL256070B (es)
MX (2) MX2017015681A (es)
TW (1) TW201717942A (es)
WO (1) WO2016196928A1 (es)
ZA (2) ZA201708233B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI433674B (zh) 2006-12-28 2014-04-11 Infinity Discovery Inc 環杷明（ｃｙｃｌｏｐａｍｉｎｅ）類似物類
CA2769795C (en) 2009-08-05 2020-01-07 Infinity Pharmaceuticals, Inc. Enzymatic transamination of cyclopamine analogs
WO2012037217A1 (en) 2010-09-14 2012-03-22 Infinity Pharmaceuticals, Inc. Transfer hydrogenation of cyclopamine analogs
MX2017015681A (es) 2015-06-04 2018-09-11 Pellepharm Inc Formulaciones topicas para suministrar compuestos inhibidores de hedgehog y uso de los mismos.
CN108567740A (zh) * 2017-03-14 2018-09-25 山西振东先导生物科技有限公司 环巴明脂肪乳注射液及其制备方法
US10821075B1 (en) * 2017-07-12 2020-11-03 James Blanchard Compositions for topical application of a medicaments onto a mammalian body surface

Family Cites Families (141)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6333341A (ja) 1986-07-28 1988-02-13 Seitetsu Kagaku Co Ltd 配糖体の処理方法
US4843071A (en) 1986-12-05 1989-06-27 Serotonin Industries Of Charleston Method and composition for treating obesity, drug abuse, and narcolepsy
JP2851054B2 (ja) 1989-03-15 1999-01-27 サントリー株式会社 ベンズオキセピン誘導体
US5169780A (en) 1989-06-22 1992-12-08 Celgene Corporation Enantiomeric enrichment and stereoselective synthesis of chiral amines
FR2656310B1 (fr) 1989-12-22 1992-05-07 Roussel Uclaf Nouveaux produits sterouides comportant en position 10, un radical thioethyle substitue, leur procede de preparation et les intermediaires de ce procede, leur application comme medicaments et les compositions pharmaceutiques les renfermant.
US5378475A (en) 1991-02-21 1995-01-03 University Of Kentucky Research Foundation Sustained release drug delivery devices
JP3546886B2 (ja) 1993-03-10 2004-07-28 ジェネーラ コーポレーション ステロイド誘導体、それらを含む薬剤組成物、及び抗生物質又は消毒薬としてのそれらの使用
IT1265001B1 (it) * 1993-12-16 1996-10-17 Zambon Spa Composizione farmaceutica per uso topico contenente acido (s)-2-(4- isobutilfenil) propionico
AU704178B2 (en) 1993-12-30 1999-04-15 Imperial Cancer Research Technology Ltd Vertebrate embryonic pattern-inducing hedgehog-like proteins
US6281332B1 (en) 1994-12-02 2001-08-28 The Johns Hopkins University School Of Medicine Hedgehog-derived polypeptides
AU7364896A (en) 1995-10-10 1997-04-30 Marilyn Strube Treatment of pruritus with vitamin d and analogs thereof
US6184381B1 (en) 1995-12-06 2001-02-06 Japan Science & Technology Corp. Process for preparing optically active compounds
US6887820B1 (en) 1995-12-06 2005-05-03 Japan Science And Technology Corporation Method for producing optically active compounds
GB9706321D0 (en) 1997-03-26 1997-05-14 Zeneca Ltd Catalytic hydrogenation
US7741298B2 (en) 1997-06-20 2010-06-22 New York University Method and compositions for inhibiting tumorigenesis
US7709454B2 (en) 1997-06-20 2010-05-04 New York University Methods and compositions for inhibiting tumorigenesis
US6238876B1 (en) 1997-06-20 2001-05-29 New York University Methods and materials for the diagnosis and treatment of sporadic basal cell carcinoma
US7361336B1 (en) 1997-09-18 2008-04-22 Ivan Bergstein Methods of cancer therapy targeted against a cancer stem line
US6231875B1 (en) 1998-03-31 2001-05-15 Johnson & Johnson Consumer Companies, Inc. Acidified composition for topical treatment of nail and skin conditions
US6432970B2 (en) 1998-04-09 2002-08-13 Johns Hopkins University School Of Medicine Inhibitors of hedgehog signaling pathways, compositions and uses related thereto
US7291626B1 (en) 1998-04-09 2007-11-06 John Hopkins University School Of Medicine Inhibitors of hedgehog signaling pathways, compositions and uses related thereto
US6867216B1 (en) 1998-04-09 2005-03-15 Johns Hopkins University School Of Medicine Inhibitors of hedgehog signal pathways, compositions and uses related thereto
CA2339330A1 (en) 1998-08-13 2000-02-24 University Of Southern California Methods to increase blood flow to ischemic tissue
GB9821067D0 (en) 1998-09-29 1998-11-18 Zeneca Ltd Transfer hydrogenation process
US6291516B1 (en) 1999-01-13 2001-09-18 Curis, Inc. Regulators of the hedgehog pathway, compositions and uses related thereto
FR2796938B1 (fr) 1999-07-29 2004-04-02 Ppg Sipsy Nouveaux derives chiraux n-substitues de la norephedrine, leur preparation et leur utilisation pour la synthese de composes fonctionnalises optiquement actifs par transfert d'hydrogene
US20070021493A1 (en) 1999-09-16 2007-01-25 Curis, Inc. Mediators of hedgehog signaling pathways, compositions and uses related thereto
EP1516876A1 (en) 1999-09-16 2005-03-23 Curis, Inc. Mediators of hedgehog signalling pathways, compositions and uses related thereto
US6993456B2 (en) 1999-09-30 2006-01-31 Rockwell Automation Technologies, Inc. Mechanical-electrical template based method and apparatus
ATE328002T1 (de) 1999-10-13 2006-06-15 Univ Johns Hopkins Med Verbindungen zur regulierung des hedgehog- signalwegs, zusammensetzungen und verwendungen davon
US6552016B1 (en) 1999-10-14 2003-04-22 Curis, Inc. Mediators of hedgehog signaling pathways, compositions and uses related thereto
CA2388468C (en) 1999-10-14 2011-01-25 Curis, Inc. Mediators of hedgehog signalling pathways, compositions and uses related thereto
US6893637B1 (en) 1999-10-21 2005-05-17 Zymogenetics, Inc. Method of treating fibrosis
IL133809A0 (en) 1999-12-30 2001-04-30 Yeda Res & Dev Steroidal alkaloids and pharmaceutical compositions comprising them
US6613798B1 (en) 2000-03-30 2003-09-02 Curis, Inc. Small organic molecule regulators of cell proliferation
ATE305786T1 (de) 2000-03-30 2005-10-15 Curis Inc Kleine organische moleküle als regulatoren der zellproliferation
AU2001264595A1 (en) 2000-05-19 2001-12-03 Guilford Pharmaceuticals Inc. Sulfonamide and carbamide derivatives of 6(5h)phenanthridinones and their uses
US7708998B2 (en) 2000-10-13 2010-05-04 Curis, Inc. Methods of inhibiting unwanted cell proliferation using hedgehog antagonists
WO2002030462A2 (en) 2000-10-13 2002-04-18 Curis, Inc. Hedgehog antagonists, methods and uses related thereto
GB0029356D0 (en) 2000-12-01 2001-01-17 Avecia Ltd Transfer hydrogenation
US6456928B1 (en) 2000-12-29 2002-09-24 Honeywell International Inc. Prognostics monitor for systems that are subject to failure
CA2440884C (en) * 2001-03-16 2012-05-22 Alza Corporation Transdermal patch for administering fentanyl
AU2002247847A1 (en) 2001-04-09 2002-10-21 Lorantis Limited Therapeutic use and identification of modulators of a hedgehog signalling pathway or one of its target pathways
AUPR602401A0 (en) 2001-06-29 2001-07-26 Smart Drug Systems Inc Sustained release delivery system
CA2452152A1 (en) 2001-07-02 2002-10-10 Sinan Tas Use of cyclopamine in the treatment of psoriasis
EP2216022B1 (en) 2001-07-02 2015-01-07 Sinan Tas Use of cyclopamine in the treatment of basal cell carcinoma and other tumors
PL366799A1 (en) 2001-07-27 2005-02-07 Curis, Inc. Mediators of hedgehog signaling pathways, compositions and uses related thereto
JP2003192919A (ja) 2001-10-17 2003-07-09 Asahi Denka Kogyo Kk 難燃性合成樹脂組成物
EP1446408A1 (en) 2001-11-09 2004-08-18 Yun Chi Volatile noble metal organometallic complexes
US7105637B2 (en) 2002-02-15 2006-09-12 William Marsh Rice University Dehydro-estriol (8-DHE3) and dehydro-pregnanetriol (7-DHPT), methods of their synthesis
US6941948B2 (en) 2002-03-07 2005-09-13 Vectura Drug Delivery Medicament storage and delivery devices
CA2483311A1 (en) 2002-04-22 2003-10-30 Philip A. Beachy Modulators of hedgehog signaling pathways, compositions and uses related thereto
CN1380060A (zh) * 2002-04-28 2002-11-20 中国人民解放军第二军医大学 外用抗真菌药物的溶液型喷雾剂及其制备方法
GB0210234D0 (en) 2002-05-03 2002-06-12 Novartis Ag Process for the manufacture of organic compounds
US20050203061A1 (en) 2002-06-20 2005-09-15 Shinya Yamashita Prodrug, medicinal utilization thereof and process for producing the same
WO2004020599A2 (en) 2002-08-29 2004-03-11 Curis, Inc. Hedgehog antagonists, methods and uses related thereto
GB0221539D0 (en) 2002-09-17 2002-10-23 Medical Res Council Methods of treatment
GB0230217D0 (en) 2002-12-27 2003-02-05 Biotica Tech Ltd Borrelidin-producing polyketide synthase and its uses
FR2850022B1 (fr) 2003-01-22 2006-09-08 Centre Nat Rech Scient Nouvelle utilisation de la mifepristone et de ses derives comme modulateurs de la voie de signalisation des proteines hedgehog et ses applications
EP1639097B1 (en) 2003-06-25 2013-08-07 Ottawa Health Research Institute Methods and compositions for modulating stem cell growth and differentiation
WO2005013800A2 (en) 2003-07-15 2005-02-17 The Johns Hopkins University Elevated hedgehog pathway activity in digestive system tumors, and methods of treating digestive system tumors having elevated hedgehog pathway activity
WO2005033288A2 (en) 2003-09-29 2005-04-14 The Johns Hopkins University Hedgehog pathway antagonists
US20070231828A1 (en) 2003-10-01 2007-10-04 Johns Hopkins University Methods of predicting behavior of cancers
US20080095761A1 (en) 2003-10-01 2008-04-24 The Johns Hopkins University Hedgehog Signaling in Prostate Regeneration Neoplasia and Metastasis
US20080057071A1 (en) 2003-10-20 2008-03-06 Watkins David N Use Of Hedgehog Pathway Inhibitors In Small-Cell Lung Cancer
US20070219250A1 (en) 2003-11-28 2007-09-20 Romi Singh Pharmaceutical Compositions of Nateglinide
EP1745041B1 (en) 2004-04-30 2012-06-20 Genentech, Inc. Quinoxaline inhibitors of the hedgehog signalling pathway
CA2579078C (en) 2004-08-27 2016-11-22 Infinity Pharmaceuticals, Inc. Cyclopamine analogues and methods of use thereof
EA201890903A9 (ru) 2004-09-02 2021-11-10 Дженентек, Инк. Соединения пиридиловых ингибиторов передачи сигналов белком hedgehog, способ их получения, композиция и способы лечения рака и ингибирований ангиогенеза и сигнального пути hedgehog в клетках на их основе
US20070281040A1 (en) 2004-09-30 2007-12-06 The University Of Chicago Combination therapy of hedgehog inhibitors, radiation and chemotherapeutic agents
RU2007119637A (ru) 2004-10-28 2008-12-10 Айрм Ллк (Bm) Соединения и композиции в качестве модуляторов hedgehog-пути
US20090208579A1 (en) 2004-12-27 2009-08-20 Eisai R & D Management Co., Ltd. Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same
US20060252073A1 (en) 2005-04-18 2006-11-09 Regents Of The University Of Michigan Compositions and methods for the treatment of cancer
WO2006124700A2 (en) 2005-05-12 2006-11-23 Introgen Therapeutics, Inc. P53 vaccines for the treatment of cancers
US8653083B2 (en) 2005-08-22 2014-02-18 The Johns Hopkins University Hedgehog pathway antagonists to treat disease
CA2625210A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
WO2007056135A1 (en) 2005-11-04 2007-05-18 Merck & Co., Inc. Method of treating cancers with saha and pemetrexed
WO2007054623A2 (en) 2005-11-11 2007-05-18 Licentia Oy Mammalian hedgehog signaling inhiabitors
CA2629814C (en) 2005-11-14 2013-12-31 Genentech, Inc. Bisamide inhibitors of hedgehog signaling
WO2007076294A2 (en) 2005-12-15 2007-07-05 Wei Chen Method of screening the activity of the smoothened receptor to identify theraputic modulation agents or diagnose disease
EP1978973B1 (en) 2005-12-27 2011-11-16 Genentech, Inc. Use hedgehog kinase antagonists to inhibit hedgehog signaling and to treat cancer
EP1818411A1 (en) 2006-02-13 2007-08-15 Lonza AG Process for the preparation of optically active chiral amines
WO2008121102A2 (en) 2006-02-21 2008-10-09 The Regents Of The University Of Michigan Hedgehog signaling pathway antagonist cancer treatment
WO2007123511A2 (en) 2006-03-24 2007-11-01 Infinity Pharmaceuticals, Inc. Dosing regimens for the treatment of cancer
BRPI0710723A2 (pt) 2006-04-14 2012-01-31 Novartis Ag uso de biarilcarboxamidas no tratamento de distúrbio relacionados à série de reação hedgehog
UA93548C2 (uk) 2006-05-05 2011-02-25 Айерем Елелсі Сполуки та композиції як модулятори хеджхогівського сигнального шляху
US20100048944A1 (en) 2006-07-19 2010-02-25 Farhad Parhami Interactions of hedgehog and liver x receptor signaling pathways
PE20080948A1 (es) 2006-07-25 2008-09-10 Irm Llc Derivados de imidazol como moduladores de la senda de hedgehog
US20090305338A1 (en) 2006-09-29 2009-12-10 Anneli Ritala-Nurmi Plant cell lines established from the medicinal plant veratrum californicum
WO2008073558A2 (en) 2006-10-05 2008-06-19 The Johns Hopkins University Water-dispersible oral, parenteral, and topical formulations for poorly water soluble drugs using smart polymeric nanoparticles
WO2008070357A2 (en) 2006-10-31 2008-06-12 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Smoothened polypeptides and methods of use
US20080103116A1 (en) 2006-11-01 2008-05-01 Jennings-Spring Barbara L Method of treatment and compositions of D-chiro inositol and phosphates thereof
US20080182859A1 (en) 2006-11-02 2008-07-31 Curis, Inc. Small organic molecule regulators of cell proliferation
EP2073637A4 (en) 2006-11-20 2011-12-28 Satori Pharmaceuticals Inc COMPOUNDS USEFUL FOR TREATING NEURODEGENERATIVE DISEASES
TWI433674B (zh) 2006-12-28 2014-04-11 Infinity Discovery Inc 環杷明（ｃｙｃｌｏｐａｍｉｎｅ）類似物類
US20100099116A1 (en) 2007-01-12 2010-04-22 Infinity Discovery, Inc. Methods for Analysis of Hedgehog Pathway Inhibitors
NZ579361A (en) 2007-03-07 2012-04-27 Infinity Discovery Inc Heterocyclic cyclopamine analogs and methods of use thereof
CA2679845A1 (en) 2007-03-07 2008-09-12 Infinity Discovery, Inc. Cyclopamine lactam analogs and methods of use thereof
KR20090130051A (ko) 2007-03-14 2009-12-17 엑셀리시스, 인코포레이티드 헤지호그 경로의 억제제
DK2137162T3 (en) 2007-03-15 2018-11-26 Novartis Ag Organic compounds and their applications
US9095589B2 (en) 2007-04-05 2015-08-04 Johns Hopkins University Chirally pure isomers of itraconazole for use as angiogenesis inhibitors
CN101663033B (zh) 2007-04-18 2013-01-16 默沙东公司 作为smo拮抗剂的三唑衍生物
WO2008131354A2 (en) 2007-04-20 2008-10-30 The Curators Of The University Of Missouri Phytoestrogens as regulators of hedgehog signaling and methods of their use in cancer treatment
EP2175863B1 (en) 2007-07-09 2018-03-21 Eastern Virginia Medical School Substituted nucleoside derivatives with antiviral and antimicrobial properties
US8636982B2 (en) * 2007-08-07 2014-01-28 Foamix Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
TW200918521A (en) 2007-08-31 2009-05-01 Astrazeneca Ab Heterocyclic amides and methods of use thereof
WO2009049258A1 (en) 2007-10-12 2009-04-16 The Johns Hopkins University Compounds for hedgehog pathway blockade in proliferative disorders, including hematopoietic malignancies
BRPI0820856A2 (pt) 2007-12-13 2019-05-14 Siena Bhiotech.S.P.A. anatagonista da série de reação de hedgehog e aplicações terapêuticas dos mesmos
US20100297118A1 (en) 2007-12-27 2010-11-25 Macdougall John Therapeutic Cancer Treatments
AU2008345097A1 (en) 2007-12-27 2009-07-09 Infinity Pharmaceuticals, Inc. Methods for stereoselective reduction
US20100222287A1 (en) 2007-12-27 2010-09-02 Mcgovern Karen J Therapeutic Cancer Treatments
AU2008345151A1 (en) 2007-12-27 2009-07-09 Infinity Pharmaceuticals, Inc. Therapeutic cancer treatments
WO2009099625A2 (en) 2008-02-08 2009-08-13 The Board Of Regents Of The University Of Texas System Cyclopamine tartrate salt and uses thereof
US20090246841A1 (en) 2008-03-26 2009-10-01 Jamieson Andrew C Methods and compositions for production of acetaldehyde
US20110217294A1 (en) 2008-04-11 2011-09-08 Daniel Fults Combination of hgf inhibitor and hedgehog inhibitor to treat cancer
CL2009001479A1 (es) 2008-07-02 2010-01-04 Infinity Pharmaceuticals Inc Metodo para aislar un alcaloide del veratrum desglicosilado que comprende proporcionar un material de planta veratrum, poner en contacto con una solucion acuosa y extraer el material de la planta veratrum con un solvente para proporcionar un extracto que comprende dicho alcaloide.
CA2636807A1 (en) 2008-07-04 2010-01-04 Steven Splinter Methods for obtaining cyclopamine
US20100041663A1 (en) 2008-07-18 2010-02-18 Novartis Ag Organic Compounds as Smo Inhibitors
US8063043B2 (en) 2008-09-17 2011-11-22 Novartis Ag Salts of N-[6-cis-2,6-dimethylmorpholin-4-yl)pyridine-3-yl]-2-methyl-4′-(trifluoromethoxy)[1,1′-biphenyl]-3-carboxamide
EP2342221B1 (en) 2008-09-22 2018-11-07 Aileron Therapeutics, Inc. Methods for preparing purified polypeptide compositions
US20100081637A1 (en) 2008-10-01 2010-04-01 Innovia Skincare Corp. Eczema treatment with vitamin D and analogs thereof method, composition and cream
KR20100051923A (ko) * 2008-11-09 2010-05-19 박은석 이트라코나졸을 함유하는 국소 적용제
WO2010085654A1 (en) 2009-01-23 2010-07-29 Cancer Research Technology Limited Hedgehog pathway inhibitors
AR077014A1 (es) 2009-06-19 2011-07-27 Lilly Co Eli Compuesto derivado de ftalazina 1,4-disustituida, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para el tratamiento de cancer
AR077490A1 (es) 2009-07-21 2011-08-31 Novartis Ag Composiciones farmaceuticas topicas para el tratamiento de una condicion hiperproliferativa de la piel
CA2769795C (en) 2009-08-05 2020-01-07 Infinity Pharmaceuticals, Inc. Enzymatic transamination of cyclopamine analogs
KR20120099715A (ko) * 2009-11-06 2012-09-11 인피니티 파마슈티칼스, 인코포레이티드 헷지혹 경로 억제제의 경구용 포뮬레이션
JP2013511549A (ja) 2009-11-20 2013-04-04 インフィニティー ファーマシューティカルズ， インコーポレイテッド ヘッジホッグ関連癌の治療のための方法及び組成物
US20110183948A1 (en) 2010-01-15 2011-07-28 Infinity Pharmaceuticals, Inc. Treatment of fibrotic conditions using hedgehog inhibitors
GB201010954D0 (en) * 2010-06-29 2010-08-11 Edko Pazarlama Tanitim Ticaret Compositions
US20120010229A1 (en) 2010-07-08 2012-01-12 Macdougall John R Therapeutic regimens for hedgehog-associated cancers
WO2012006589A2 (en) 2010-07-08 2012-01-12 Infinity Pharmaceuticals, Inc. Methods and compositions for identification, assessment and treatment of cancers associated with hedgehog signaling
WO2012037217A1 (en) 2010-09-14 2012-03-22 Infinity Pharmaceuticals, Inc. Transfer hydrogenation of cyclopamine analogs
CN102085176A (zh) * 2010-12-31 2011-06-08 江苏中丹制药有限公司 一种纳米级伊曲康唑外用制剂、其制备方法及其用途
US8865765B2 (en) 2011-01-12 2014-10-21 The William M. Yarbrough Foundation Method for treating eczema
US9072660B2 (en) 2011-09-09 2015-07-07 The Board Of Trustees Of The Leland Stanford Junior University Topical itraconazole formulations and uses thereof
US9630979B2 (en) * 2011-09-29 2017-04-25 Infinity Pharmaceuticals, Inc. Inhibitors of monoacylglycerol lipase and methods of their use
KR20150093702A (ko) 2012-12-14 2015-08-18 트레비 테라퓨틱스, 인코포레이티드 소양증을 치료하는 방법
SG11201607973XA (en) 2014-03-24 2016-11-29 Guangdong Zhongsheng Pharmaceutical Co Ltd Quinoline derivatives as smo inhibitors
MX2017015681A (es) 2015-06-04 2018-09-11 Pellepharm Inc Formulaciones topicas para suministrar compuestos inhibidores de hedgehog y uso de los mismos.
WO2017139497A1 (en) 2016-02-11 2017-08-17 PellePharm, Inc. Hedgehog inhibitor for use in relief of and treatment of pruritus or itching

Also Published As

Publication number Publication date
BR112017026103B1 (pt) 2023-10-03
US10695344B2 (en) 2020-06-30
JP2021014469A (ja) 2021-02-12
US20190134027A1 (en) 2019-05-09
CA2988289C (en) 2023-12-05
HK1253345A1 (zh) 2019-06-14
CA2988289A1 (en) 2016-12-08
TW201717942A (zh) 2017-06-01
ZA201808543B (en) 2020-02-26
ZA201708233B (en) 2019-12-18
JP2018516989A (ja) 2018-06-28
AU2016271468A1 (en) 2017-12-21
US20200383975A1 (en) 2020-12-10
US10369147B2 (en) 2019-08-06
IL256070A (en) 2018-01-31
JP6796638B2 (ja) 2020-12-09
US11413283B2 (en) 2022-08-16
WO2016196928A1 (en) 2016-12-08
MX2017015681A (es) 2018-09-11
BR112017026103A2 (es) 2018-08-21
US20160354368A1 (en) 2016-12-08
EP3302428A1 (en) 2018-04-11
AU2016271468B2 (en) 2020-01-02
IL256070B (en) 2022-01-01
MX2021011424A (es) 2021-10-13

Similar Documents

Publication Publication Date Title
CL2017003091A1 (es) Formulaciones tópicas para la entrega de compuestos inhibidores hedgehog y uso de los mismos
CL2018000730A1 (es) Compuestos heterocíclicos y usos de los mismos
CL2019001664A1 (es) Compuestos heterocíclicos sustituidos con amina como inhibidores de ehmt2 y métodos de uso de los mismos.
CL2018002410A1 (es) Inhibidores de mcl-1 y métodos de uso de los mismos
CL2017000902A1 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
PE20160541A1 (es) Formulaciones de anticuerpos anti-pdl1
CL2016000508A1 (es) Compuestos derivados de (2-metil-3-fenilfenil)metoxi sustituidos, inhibidores de la interacción pd-1/proteína pd-l1/proteína; composición farmacéutica que los comprende; y su uso para tratar una enfermedad infecciosa o cáncer.
CL2016002877A1 (es) Compuestos de 2-cloro-2-difluorometoxifenil pirazolopirimidina, composiciones y métodos de uso de los mismos.
CL2016000925A1 (es) Inhibidores de bromodominio
CL2016001537A1 (es) Inhibidores de syk
DOP2016000094A (es) Compuestos derivados de piridilo bicíclicos fusionados a anillo como inhibidores de fgfr4.
CL2014002096A1 (es) Compuestos heterocíclicos que comprenden un sistema enediino; conjugados de los mismos; composiciones que los comprenden; y uso para tratar el cáncer
GT201700023A (es) Derivados de heterociclico opcionalmente condensados de piridimina útiles para el tratamiento de enfermedades inflamatorias, metabolicas, oncológicas y autoinmunitarias
UY36342A (es) Nuevos derivados de aminoalquilbenzotiazepinas y usos de los mismos
CL2014002093A1 (es) Compuestos derivados piperidinopirimidinicos; composicion farmaceutica que los comprende; uso en el tratamiento de infecciones viricas.
CL2017001923A1 (es) Derivados de 9h-pirrolo-dipiridina
AU2020239804B2 (en) Transdermal formulations
CO2018002211A2 (es) Piridinona dicarboxamida para su uso como inhibidores de bromodominio
PE20150646A1 (es) Metodos de tratamiento de una tauopatia
CL2016000063A1 (es) Nuevos derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen.
CL2016001232A1 (es) Inhibidores tetracíclicos de autotaxina
CL2015002060A1 (es) Compuestos.
UY35455A (es) Inhibidores tripeptidicos de la epoxicetona proteasa
BR112019006414A2 (pt) análogos de carbanucleosídeos de sistema de anel monocíclico e bicíclico substituídos para uso como inibidores de prmt5
DOP2016000007A (es) Pirazolpiridinas sustituidas